144 related articles for article (PubMed ID: 38145494)
1. Atypical mutation of epidermal growth factor receptor in resected stage I non-small-cell lung cancers.
Etienne H; Goudou T; Assouad J
Eur J Cardiothorac Surg; 2024 Jan; 65(1):. PubMed ID: 38145494
[No Abstract] [Full Text] [Related]
2. Concomitant Genetic Alterations With Response to Treatment and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With EGFR-Mutant Advanced Non-Small Cell Lung Cancer.
Hong S; Gao F; Fu S; Wang Y; Fang W; Huang Y; Zhang L
JAMA Oncol; 2018 May; 4(5):739-742. PubMed ID: 29596544
[TBL] [Abstract][Full Text] [Related]
3. Distinct clinical course of EGFR-mutant resected lung cancers: results of testing of 1118 surgical specimens and effects of adjuvant gefitinib and erlotinib.
D'Angelo SP; Janjigian YY; Ahye N; Riely GJ; Chaft JE; Sima CS; Shen R; Zheng J; Dycoco J; Kris MG; Zakowski MF; Ladanyi M; Rusch V; Azzoli CG
J Thorac Oncol; 2012 Dec; 7(12):1815-1822. PubMed ID: 23154553
[TBL] [Abstract][Full Text] [Related]
4. Mutations in the epidermal growth factor receptor tyrosine kinase may predict response to gefitinib in non-small-cell lung cancer.
Clin Lung Cancer; 2004 May; 5(6):331-2. PubMed ID: 15217530
[No Abstract] [Full Text] [Related]
5. Health economic analysis of epidermal growth factor receptor mutation-guided first-line therapies for advanced non-small-cell lung cancer: abridged secondary publication.
You JHS; Cho WCS; Li YC; Kwan CK; Au JSK
Hong Kong Med J; 2023 Feb; 29 Suppl 2(1):8-11. PubMed ID: 36950997
[No Abstract] [Full Text] [Related]
6. Prevalence of Epidermal Growth Factor Receptor Mutations in Patients with Non-Small Cell Lung Cancer in Turkish Population.
Güler Tezel G; Şener E; Aydın Ç; Önder S
Balkan Med J; 2017 Dec; 34(6):567-571. PubMed ID: 28832323
[TBL] [Abstract][Full Text] [Related]
7. Randomized Phase II Study of 3 Months or 2 Years of Adjuvant Afatinib in Patients With Surgically Resected Stage I-III
Neal JW; Costa DB; Muzikansky A; Shrager JB; Lanuti M; Huang J; Ramachandran KJ; Rangachari D; Huberman MS; Piotrowska Z; Kris MG; Azzoli CG; Sequist LV; Chaft JE
JCO Precis Oncol; 2021 Jan; 5():325-332. PubMed ID: 34151132
[TBL] [Abstract][Full Text] [Related]
8. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.
Lynch TJ; Bell DW; Sordella R; Gurubhagavatula S; Okimoto RA; Brannigan BW; Harris PL; Haserlat SM; Supko JG; Haluska FG; Louis DN; Christiani DC; Settleman J; Haber DA
N Engl J Med; 2004 May; 350(21):2129-39. PubMed ID: 15118073
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in the Adjuvant Setting for Patients with Resected Epidermal Growth Factor Receptor Mutant Non-Small Cell Lung Cancer: A Meta-Analysis with 11 Trials.
Yin Q; Xun X; Yang G; Cui H; Liu H
Oncol Res Treat; 2021; 44(6):344-353. PubMed ID: 33951671
[TBL] [Abstract][Full Text] [Related]
10. [Clinical research and drug review of epidermal growth factor receptor tyrosine kinase inhibitors in advanced non-small cell lung cancer].
Zhou M; Chen DM; Xia L; Song YY; Shi YK; Yang ZM
Zhonghua Zhong Liu Za Zhi; 2019 Dec; 41(12):949-952. PubMed ID: 31874554
[TBL] [Abstract][Full Text] [Related]
11. Role of epidermal growth factor receptor mutations in predicting sensitivity or resistance to targeted agents in non-small-cell lung cancer.
Reddy GK
Clin Lung Cancer; 2005 May; 6(6):338-9. PubMed ID: 15943892
[No Abstract] [Full Text] [Related]
12. Tyrosine kinase inhibitors for epidermal growth factor receptor gene mutation-positive non-small cell lung cancers: an update for recent advances in therapeutics.
Chung C
J Oncol Pharm Pract; 2016 Jun; 22(3):461-76. PubMed ID: 25855240
[TBL] [Abstract][Full Text] [Related]
13. Epidermal growth factor receptor inhibitors as adjuvant treatment for patients with resected non-small cell lung cancer harboring EGFR mutation: a meta-analysis of randomized controlled clinical trials.
Zhao N; Wu ZP; Yang J; Feng WN; Yang SL; Luo Y; Ye J; Wang F; Zhang XW; Xiao Y; Wu LL; Gu WQ
World J Surg Oncol; 2023 Feb; 21(1):45. PubMed ID: 36782320
[TBL] [Abstract][Full Text] [Related]
14. Osimertinib in Resected
Wu YL; Tsuboi M; He J; John T; Grohe C; Majem M; Goldman JW; Laktionov K; Kim SW; Kato T; Vu HV; Lu S; Lee KY; Akewanlop C; Yu CJ; de Marinis F; Bonanno L; Domine M; Shepherd FA; Zeng L; Hodge R; Atasoy A; Rukazenkov Y; Herbst RS;
N Engl J Med; 2020 Oct; 383(18):1711-1723. PubMed ID: 32955177
[TBL] [Abstract][Full Text] [Related]
15. Clinical Factors Predicting Detection of T790M Mutation in Rebiopsy for EGFR-Mutant Non-small-cell Lung Cancer.
Kawamura T; Kenmotsu H; Omori S; Nakashima K; Wakuda K; Ono A; Naito T; Murakami H; Omae K; Mori K; Tanigawara Y; Nakajima T; Ohde Y; Endo M; Takahashi T
Clin Lung Cancer; 2018 Mar; 19(2):e247-e252. PubMed ID: 28866043
[TBL] [Abstract][Full Text] [Related]
16. Characteristics and overall survival of EGFR mutation-positive non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors: a retrospective analysis for 1660 Japanese patients.
Inoue A; Yoshida K; Morita S; Imamura F; Seto T; Okamoto I; Nakagawa K; Yamamoto N; Muto S; Fukuoka M
Jpn J Clin Oncol; 2016 May; 46(5):462-7. PubMed ID: 26977054
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of Next-Generation EGFR-TKIs in Patients With Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials.
Qi YT; Hou Y; Qi LC
Technol Cancer Res Treat; 2020; 19():1533033820940426. PubMed ID: 32723164
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of chemotherapy after first-line gefitinib therapy in EGFR mutation-positive advanced non-small cell lung cancer-data from a randomized Phase III study comparing gefitinib with carboplatin plus paclitaxel (NEJ002).
Miyauchi E; Inoue A; Kobayashi K; Maemondo M; Sugawara S; Oizumi S; Isobe H; Gemma A; Saijo Y; Yoshizawa H; Hagiwara K; Nukiwa T;
Jpn J Clin Oncol; 2015 Jul; 45(7):670-6. PubMed ID: 25877748
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant TKIs - a long-term matter.
Romero D
Nat Rev Clin Oncol; 2019 Feb; 16(2):67. PubMed ID: 30487531
[No Abstract] [Full Text] [Related]
20. Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer.
Pao W; Chmielecki J
Nat Rev Cancer; 2010 Nov; 10(11):760-74. PubMed ID: 20966921
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]